Despite rising short interest, Forte Biosciences receives "buy" ratings as CFO boosts stock ownership.

Forte Biosciences, a biopharmaceutical company developing treatments for autoimmune diseases, saw short interest increase by nearly 20% in January, reaching 342,900 shares. Despite this, analysts at TD Cowen and Chardan Capital issued "buy" ratings with a $64 price target. The company's CFO recently increased his stock ownership by 272.50%. Forte Biosciences has a market cap of $23.20 million.

6 weeks ago
58 Articles

Further Reading